The Drug Discovery World Podcast DDW Highlights: 2 June 2025
Jun 2, 2025
A major deal between Eli Lilly and Rznomics marks a significant leap in RNA-editing therapies. There's also promising research aimed at improving the quality of life for Parkinson's patients. Discover the innovative approaches from Courage Therapeutics in obesity treatment and Poolbeg Pharma’s new cancer immunotherapy. This exciting week highlights the relentless progress and hope within the drug discovery landscape!
AI Snips
Chapters
Transcript
Episode notes
RNA Editing Therapy Collaboration
- The Eli Lilly and Risnomics partnership targets RNA-editing therapies for sensorineural hearing loss using a unique trans-splicing ribozyme platform.
- This collaboration could unlock transformative precision RNA therapeutics, marking a major development in treating difficult diseases.
Ghrelin Receptor Key in Parkinson's
- Ghrelin receptor plays a key role in spinal defecation control affected by Parkinson's disease, explaining chronic constipation in up to 90% of patients.
- Targeting this receptor could improve bowel function and overall quality of life for Parkinson's sufferers.
Melanocortin Targeting in Obesity
- Courage Therapeutics develops drugs targeting melanocortin receptors to treat obesity and restrictive eating disorders via brain's energy regulation circuits.
- Their approach bypasses gut hormone pathways, offering potential synergy with existing treatments like GLP-1 drugs.